

## MEDESIS PHARMA RECOGNIZED AS A 2023 PRIX GALIEN USA NOMINEE FOR BEST STARTUP

Montpellier, August 3, 2023 at 6:00 p.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active pharmaceutical ingredients in nanomicelles by the buccal route, Aonys®, announces today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, in partnership with Business France, named Medesis Pharma a 2023 Prix Galien USA Award nominee for “Best Startup.”

As a clinical-stage pharmaceutical biotechnology company developing innovative technology (Aonys®) for the delivery of therapeutic molecules to treat diseases with no current efficacious treatment, MEDESIS PHARMA has been named for the “Prix Galien Startup” category, which rewards and supports innovation worldwide.

The Prix Galien was created in France in 1970 to reward innovative treatments and technologies that improve human health. The 2023 Prix Galien USA Medical Technology, Digital Health, Incubators, Accelerators and Equity, and Startup Awards Committee is composed of nine renowned leaders from the biomedical industry and academia, responsible for evaluating nominees.



« The Prix Galien Awards Committee is delighted to celebrate this remarkable group of candidates and selecting this year’s winners will be no easy feat,” said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Medical Technology, Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. “This great list of nominees reflects the undeniable courage, dedication, and passion behind each researcher continually working to deliver answers to patients around the world »

Winners will be announced during the Prix Galien USA Forum on October 26, 2023, at the Alexandria Center for Life Science in New York City.

For more information and the full list of nominees, visit: <https://galien.org/3KfByHU>

### About the Galien Foundation

The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit [www.galienfoundation.org](http://www.galienfoundation.org).

### About Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. For further information, visit [www.businessfrance.fr](http://www.businessfrance.fr).

### About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer’s disease, Huntington’s disease, and resistant cancers.



Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, the result of 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information: [www.medesispharma.com](http://www.medesispharma.com)

**MEDESIS PHARMA**

Jean Claude Maurel  
Tel: +33 4 67 03 03 96  
[contact@medesispharma.com](mailto:contact@medesispharma.com)

**CALYPTUS**

Marie Calleux  
Tel : +33 1 53 65 68 66  
[medesispharma@calyptus.net](mailto:medesispharma@calyptus.net)